Your browser does not support JavaScript or it may be disabled!
rediff.com
 India As It Happens
Rediff Labs will showcase innovative products that rediff is working on behind the scenes.
News   |   Images
NEWS ON MOBILE
Get Realtime News
on your webpage

About 205 results for "gilead sciences"

Market Update: Gilead Sciences Inc (NASDAQ:GILD)  Gilead Sciences to Release First Quarter 2014 Financial Results on Tuesday, April 22, 2014
Jutia Group

Gilead Sciences (GILD) Crosses Pivot Point Resistance at $69.68

Shares of Gilead Sciences (NASDAQ:GILD) have bullishly opened above the pivot of $67.63 today and have reached the first resistance level of $69.68. Analysts will be watching for a cross of the next upside pivot targets of $71.18 Individual.com, 15 hours ago
[x]  

169 images for gilead sciences

American Banking News, 9 hours ago
Jutia Group, 1 day ago
CTV News, 1 week ago
Live Trading News, 1 week ago
Jutia Group, 5 days ago
San Francisco Chronicle, 4 days ago
Medical Marketing And Media, 2 days ago
Jutia Group, 1 week ago
American Banking News, 3 weeks ago
Jutia Group, 2 weeks ago

Gilead aims to license hepatitis C drug to 3-4 Indian firms

LONDON (Reuters) - Gilead Sciences aims to license its new hepatitis C drug Sovaldi to three or four Indian generic manufacturers to allow sales of the medicine at lower prices in some 60 developing nations. Clifford Samuel, head of access operations and ...
 Business Standard1 week ago
Business Line

What made Gilead Sciences choose Mylan as India partner

Manufacturing capacity, quality and ethical approach proved winners February 11, 2014: Last month, California-based Gilead Sciences expanded its alliance with fellow multinational Mylan to bring its branded medicines into India. In an interview with PT Jyothi ...
 Business Line2 months ago Mylan to sell Gilead's branded drugs in India  Business Standard2 months ago Mylan is now Gileads branded medicine partner in India  Business Line2 months ago
Business Standard

Gilead to license hep-C drug to low-cost manufacturers

Gilead Sciences plans to license its breakthrough hepatitis C drug Sovaldi to a number of Indian generic pharmaceutical manufacturers, allowing for lower-priced sales of the medication in that developing nation, according to the company. Although prices for ...
 Economic Times2 months ago Gilead to license hepatitis C drug to lower-cost manufacturers in India  Reuters2 months ago
[x]  

Texas Medicaid holds off on proposed limits for Gilead hepatitis drug

(Reuters) - Texas is reconsidering whether to impose strict limits on Gilead Sciences' $84,000 hepatitis C treatment for patients on the state's Medicaid health plan for the poor, at the urging of outside advisers, a state official said on Friday. The Texas ...
 Reuters5 days ago Exclusive: Costs to public of $84,000 hep C drug ‘outrageous' - Kaiser  Reuters2 weeks ago Gilead says has discounted hepatitis C drug for some health plans  Reuters2 weeks ago Gilead offers Egypt new hepatitis C drug at 99 percent discount  Reuters3 weeks ago

U.S. drug industry group defends price of Gilead hepatitis drug

WASHINGTON (Reuters) - The leading U.S. pharmaceutical industry trade group on Thursday defended the cost of Gilead Sciences Inc's new hepatitis C drug, Sovaldi, saying such treatments offer a priceless breakthrough for patients with the liver-destroying ...
 Reuters6 days ago US drug industry group defends price of Gilead hepatitis drug  Economic Times6 days ago
Reuters

Natco seeks to block Gilead's hepatitis C drug patent in India: source

MUMBAI (Reuters) - India's Natco Pharma Ltd has formally asked the Indian patent office to deny U.S. drugmaker Gilead Sciences Inc's new hepatitis C drug Sovaldi a patent in India, a source with direct knowledge of the matter said.
 Reuters6 days ago Natco moves to oppose Gilead hepatitis C drug patent in India - source  Business Standard6 days ago
Seeking Alpha

Gilead Sciences, Inc. Feeling Sovaldi Pressure From All Sides

One of the sparks that ignited the recent biotech sell-off was the backlash over the cost of Gilead Sciences ' ( NASDAQ: GILD ) highly effective hepatitis C therapy. While much of the industry needed a reality check, it looks like the market has ...
 Motley Fool7 hours ago Gilead Sciences May See A Healthy Earnings Beat  Seeking Alpha11 hours ago

Watch for Gilead Sciences to Potentially Pullback After Gaining 1.63% Yesterday

Gilead Sciences (NASDAQ:GILD) traded in a range yesterday that spanned from a low of $68.34 to a high of $69.89. Yesterday, the shares gained 1.6%, which took the trading range above the 3-day high of $69.14 on volume of 17.2 million shares. ...
 Individual.com8 hours ago Gilead Sciences (GILD) Showing Support Near $64.08  PredictWallStreet12 hours ago

Gilead Sciences Has Returned 12.6% Since SmarTrend Recommendation (GILD)

SmarTrend identified a Downtrend for Gilead Sciences (NASDAQ:GILD) on March 13th, 2014 at $79.02. In approximately 1 month, Gilead Sciences has returned 12.56% as of today's recent price
 Individual.com14 hours ago
Prev | Next
Personalize your Realtimeclose [x]
Add content to your personalized tab - My News
Add upto 6 topics of your interest:
for eg.2g Scam , World
1.
2.
3.
4.
5.
6.
Personalize the tabs display. ( You can add or remove the tabs )
AlertsGet updates on latest news & your favourite topics right in your inbox.Set an Alert|Manage your Alerts

Get

Realtime News

on your Webpage

Add Widget >Get your members hooked!
Related Queries - gilead sciences
    
Alerts
Get updated on latest news & your favorite topics right in your inbox!
 
More     Less